期刊文献+

多黏菌素E注射制剂及其临床应用 被引量:2

Injectable preparations and clinical applications of polymyxin E
下载PDF
导出
摘要 目的:对多黏菌素E注射制剂的相关信息以及临床应用进行综述。方法:参考近年来国内外文献,对三种多黏菌素E注射制剂的基本信息、耐药性和不良反应等进行详尽的整理和讨论,对产品的临床应用进行分类和评价。结果:三种多黏菌素E注射制剂在化学结构、给药途径、给药剂量等方面都存在差异,临床医生在使用的时候尤为需要关注。除静脉注射给药外,多黏菌素E注射制剂尚有雾化吸入、鞘内或脑室内给药以及膀胱灌注等多种给药途径的应用。结论:随着多药耐药菌的出现,多黏菌素E重新获得了青春。但是,该品种仍需进一步的深入研究,同时也需要开发适应临床需求的新品种。 Objective: To review the studies on injectable preparations and clinical application of polymyxin E. Methods: Basic information about drug resistance, adverse reactions and clinical application of three injectable preparations of polymyxin E was classified and reviewed based on recent published literatures. Results: Physicians need to focus on the differences of chemical structure, route of administration and dosage in the use of three injectable preparations of polymyxin E. In addition to intravenous administration, the routes for administration of injectable preparations of polymyxin E including inhalation, intrathecal or intraventricular administration and intravesical irrigation are common. Conclusion: With the emergence of multidrug resistant bacteria, polymyxin E rejuvenated. Further studies on the new drug and the development of new preparations adapted to clinical needs are required.
出处 《上海医药》 CAS 2013年第13期16-20,共5页 Shanghai Medical & Pharmaceutical Journal
关键词 多黏菌素E 给药途径 剂量 多药耐药菌 新品种 polymyxin E route of administration dosage multidrug resistance bacteria new preparations
  • 相关文献

参考文献18

  • 1Velkov T, Roberts KD, Nation RL, et al. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics[J]. Future Microbiol, 2013, 8(6): 711-724.
  • 2Michalopoulos AS, Karatza DC. Multidrug-resistant Gramnegative infections: the use of colistin[J]. Expert Rev Anti Infect Ther, 2010, 8(9): 1009-1017.
  • 3Oostdijk EA, Smits L, de Smet AM, et al. Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units[J]. Intensive Care Med, 2013, 39(4): 653-660.
  • 4Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new[J]. Diagn Microbiol Infect Dis, 2012, 74(3) :213-223.
  • 5Boisson M, Gregoire N, Couet W, et al. Colistin in critically ill patients[J]. Minerva Anestesiol, 2013, 79(2): 200-208.
  • 6Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing[J]. Pharmacotherapy, 2010, 30(12): 1279-1291.
  • 7Apisaranthanarak A, Rujanavech S, Luxamesathaporn P, et al. Intensified infection control measures to minimize the spread of colistin-resistant Acinetobacter baumannii[J]. Infect Control Hosp Epidemiol, 2013, 34(4): 445-447.
  • 8Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant gram- negative bacteria: a matched case-control study[J]. Crit Care Med, 2008, 36(3): 807-811.
  • 9Yahav D, Farbman L, Leibovici L, et al. Colistin: new lessons on an old antibiotic[J]. Clin Microbiol Infect, 2012, 18(1): 18- 29.
  • 10Kapoor K, Jajoo M, Dublish S, et al. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients[J]. Pediatr Crit Care Med, 2013, Epub ahead of print.

同被引文献40

  • 1Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing [J]. Pharmacotherapy, 2010, 30(12): 1279-1291.
  • 2Michalopoulos AS, Karatza DC. Multidrug-resistant Gram- negative infections: the use of colistin [J]. Expert Rev Anti Infect Ther, 2010, 8(9): 1009-1017.
  • 3Michalopoulos AS, Karatza DC; Gregorakos L. Pharmacokinetic evaluation of colistin sodium [J]. Expert Opin Drug Metab Toxicol, 2011, 7(2): 245-255.
  • 4Bergen PJ, Li J, Nation RL. Dosing of colistin -- back to basic PK/PD [J]. Curr Opin Pharmacol, 2011, 11(5): 464-469.
  • 5Jabes D. The antibiotic R&D pipeline: an update [J]. Curr Opin Microbiol, 2011, 14(5): 564-569.
  • 6Donadio S, Maffioli S, Monciardini P, et al. Antibiotic discovery in the twenty-first century: current trends and future perspectives [J]. J Antibiotics, 2010, 63(8): 423-430.
  • 7Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria [J]. Int J Antimicrob Agents, 2005, 25(1): 11-25.
  • 8Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? [J]. Clin Infect Dis, 2014, 59(1): 88-94.
  • 9Evansm E, Feola D J, Rapp RE Polymyxin B sulfate and colistin old antibiotics for emerging multiresistant Gram- negtive bacteria [J]. Ann Pbarmacother, 1999, 33(9): 960-967.
  • 10Hermsen ED, Sullivan C J, Rotschafer JC. Polymyxin: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications [J]. Infect Dis Clin North Am, 2003, 17(3): 545-562.

引证文献2

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部